Optic NeuritisMANAGEMENT

OPHTHALMOLOGIC PRESENTATIONS · 12 SECTIONS

⚲

659 items

☷ Legend

⚲

Cardiovascular Presentations71▾

Respiratory Presentations52▾

Neurological Presentations83▾

Gastrointestinal Presentations74▾

Genitourinary and Reproductive Presentations48▾

Infectious Disease Presentations148▾

Trauma Presentations89▾

Toxicologic Presentations80▾

Psychiatric Presentations26▾

Musculoskeletal and Rheumatologic Presentations96▾

Dermatology Presentations23▾

Environmental and Exposure Presentations27▾

Hematologic and Oncologic Presentations36▾

Pediatric-Specific Presentations19▾

Endocrine and Metabolic Presentations45▾

ENT and Maxillofacial Presentations27▾

Ophthalmologic Presentations19▾

Acute angle-closure glaucoma Central retinal artery occlusion Central Retinal Vein Occlusion Chemical eye injury Corneal abrasion Corneal ulcer Endophthalmitis Globe rupture Herpes zoster ophthalmicus Hyphema Iritis-Uveitis Ocular foreign body Optic Neuritis Orbital cellulitis Orbital Floor Fracture (Blowout)Posterior vitreous detachment Retinal detachment Retrobulbar hematoma and orbital compartment syndrome Vitreous Hemorrhage

Obstetric Presentations23▾

Systemic and Miscellaneous Presentations17▾

01Approach to the Critical Patient/attcp43

Immediate priorities

›Vision-threatening emergencies

›Bilateral simultaneous vision loss

›Suggests NMOSD or MOGAD — not typical MS-associated ON

›Urgent neurology consultation

›No light perception or near-NLP vision

›Severe NMOSD pattern — poor spontaneous recovery

›Immediate IV methylprednisolone and plasma exchange planning

›Concurrent myelitis

›Limb weakness, sensory level, or bladder dysfunction

›Emergent MRI brain and spine

›If vision loss with systemic features suggesting giant cell arteritis, immediate ESR/CRP and ophthalmology

›Age >50 with jaw claudication or scalp tenderness

›Cannot miss — temporal artery biopsy

Stabilization and escalation

›Escalation triggers

›Steroid-refractory or steroid-dependent vision loss

›Consider NMOSD, MOGAD, or non-demyelinating etiology

›Plasma exchange (PLEX) planning

›Area postrema syndrome

›Intractable nausea, vomiting, and hiccups

›High specificity for NMOSD

›Focal neurologic deficits beyond eye

›Escalate to neurology immediately

›Brainstem or spinal cord involvement

Monitoring targets

›Visual function monitoring

›Snellen visual acuity at presentation and through course

02History/hx70

Onset and progression

›Core symptom timeline

›Subacute monocular vision loss

›Worsens over hours to days

›Nadir typically within 1–2 weeks

›Periocular or retro-orbital pain

›Present in approximately 92% of ONTT patients

›Worsened by eye movement in 70%

›May precede visual loss in 40%

›Color desaturation

›Red objects appear washed out, pink, or orange

›Red cap test — bedside screening question

›Severity range

›Mild blurring to no light perception

›Approximately 66% have acuity 20/200 or better at nadir

Associated neurologic symptoms

›Demyelinating symptom screen

›Limb weakness or numbness

›Suggests concurrent myelitis or prior relapse

›Lhermitte sign — electric shock sensation with neck flexion

›Bladder or bowel dysfunction

›Neurogenic bladder symptoms

›Urgency, incontinence, retention

›Intractable nausea, vomiting, or hiccups

›Area postrema syndrome — high specificity for NMOSD

›Distinguish from viral illness

Alarm history features

›Atypical pattern red flags

03Physical Exam/exam47

Visual function assessment

›Acuity and pupils

›Snellen visual acuity — affected eye

›Range from 20/20 to no light perception

›Document monocular testing

›RAPD (Marcus Gunn pupil)

›Hallmark finding — ipsilateral RAPD on swinging flashlight test

›Required for ONTT enrollment — absence should prompt reconsideration

›Color vision

›Red cap desaturation test

›Ishihara plates when available

›Visual field

›Central or cecocentral scotoma most common

›Altitudinal defect — ischemic pattern, not typical ON

Fundoscopic exam

›Optic disc findings

›Normal optic disc (retrobulbar neuritis)

›Present in two-thirds of typical ON cases

›Pain with eye movement despite normal disc

›Disc swelling

›Present in approximately one-third

›Typically mild to moderate diffuse swelling in typical ON

›Atypical disc findings

›Severe disc edema — suggests MOGAD or NMOSD

›Peripapillary hemorrhages or macular exudates — not typical MS-ON

›Pallor (chronic) — suggests prior atrophic injury

Neurologic exam

›Systemic neurologic assessment

04Differential Diagnosis/ddx49

Life-threatening and vision-threatening causes

›Must-not-miss diagnoses

›Giant cell arteritis (arteritic AION)

›ICD-10 M31.6

›Age above 50, jaw claudication, scalp tenderness, elevated ESR/CRP

›Compressive optic neuropathy

›ICD-10 H47.02

›Meningioma or glioma — painless progressive loss, proptosis

›Malignant hypertensive optic neuropathy

›Bilateral disc edema, severely elevated blood pressure

›Retinal flame hemorrhages and exudates

Demyelinating subtypes

›Optic neuritis spectrum

›MS-associated ON

›ICD-10 H46.0

›Unilateral, painful, good recovery — most common subtype

›NMOSD-associated ON

›ICD-10 G36.0

›Severe, often bilateral, poor recovery, AQP4-IgG positive

›MOGAD-associated ON

›MOG-IgG positive

›Prominent disc edema, bilateral, steroid-responsive but relapse-prone

›Idiopathic isolated ON

›Seronegative without other lesions

›May represent early MS

Non-inflammatory mimics

›Ischemic and vascular

›Non-arteritic anterior ischemic optic neuropathy (NAION)

05Laboratory Tests/lt45

Core serologic workup

›Antibody panel — all atypical or severe cases

›AQP4-IgG (aquaporin-4 antibody)

›Cell-based assay preferred

›Sensitivity greater than 80%, specificity greater than 99% for NMOSD

›Positive result changes acute and long-term management dramatically

›MOG-IgG (myelin oligodendrocyte glycoprotein antibody)

›Cell-based assay required for accuracy

›ELISA has unacceptably high false-positive rate

›Positive result indicates MOGAD — distinct prognosis and treatment

›Inflammatory markers

›ESR and CRP

›Urgently required if age above 50 (GCA screen)

›Elevated supports GCA — proceed to temporal artery biopsy

›CBC and CMP

›Baseline before high-dose steroids

›Blood glucose monitoring during steroid therapy

›Renal function for dosing

Extended workup when indicated

›Autoimmune panel

›ANA — lupus-associated optic neuropathy

›Anti-dsDNA if ANA positive

›Complement levels (C3, C4)

›ACE level and chest imaging

›Sarcoidosis evaluation

›Uveitis or hilar adenopathy context

›RPR/FTA-ABS

›Syphilitic optic neuritis

06Diagnostic Tests/dt82

Scoring Systems

›MS risk stratification tools

›McDonald Criteria (2017 revision)

›Requires dissemination in space and time for MS diagnosis

›MRI lesion burden is key input

›Single ON episode with abnormal MRI can fulfill criteria

›ONTT 15-year risk data

›72% MS conversion if brain MRI shows one or more white matter lesions

›Approximately 25% MS conversion with normal brain MRI at 15 years

›No optic nerve enhancement, no brain lesions — lowest risk group

›MRI lesion count as primary risk stratifier

›Zero lesions — approximately 25% MS risk at 15 years

›One or more lesions — 72% MS risk at 15 years

›Class I evidence level (ONTT, NEJM 1992)

MRI

›MRI brain and orbits with gadolinium — first-line imaging

›Technique

›Fat-suppressed T2 (STIR or FLAIR) of orbits

›Gadolinium-enhanced T1 fat-suppressed sequences for nerve enhancement

›ACR Appropriateness Criteria — MRI orbits with and without contrast rated usually appropriate for suspected optic nerve pathology

›Acute ON findings

›T2 signal change in optic nerve

›Gadolinium enhancement of affected nerve

›Edema and enlargement

›Subtype-specific MRI patterns

›MS-associated ON — short-segment, unilateral, anterior nerve enhancement

›NMOSD — longitudinally extensive lesions, chiasmal or optic tract involvement

›MOGAD — longitudinal intraorbital lesions, perineural or orbital fat enhancement

›Brain MRI for demyelinating lesions

›Periventricular, juxtacortical, infratentorial lesions

›Number and location for McDonald criteria

›Critical for MS risk stratification and DMT decision

›MRI spine

›Indications

›Myelitis symptoms present

›NMOSD suspected

›Clarification of dissemination in space

›NMOSD spine pattern

›Longitudinally extensive transverse myelitis (3 or more vertebral segments)

›Central cord lesion

›MS spine pattern

›Short-segment, asymmetric, peripheral cord lesion

›CT limitations in optic neuritis

›Role of CT

›Not adequate for optic nerve evaluation

›MRI is the gold standard for optic nerve imaging

›CT does not visualize intraorbital nerve detail

›When CT may be used

›MRI unavailable or contraindicated (pacemaker, severe claustrophobia)

›Exclude gross bony compressive lesion (meningioma with calcification)

›Acute trauma context

›CT orbits findings

›Cannot reliably show enhancement or T2 signal

›May show optic nerve sheath meningioma tram-track calcification

›Proptosis or bony orbital lesion assessment

Ultrasound

›Orbital ultrasound (B-scan and optic nerve sheath diameter)

›Optic nerve sheath diameter (ONSD)

›Elevated ONSD greater than 5.8 mm suggests raised intracranial pressure

›Useful screen for papilledema versus true optic neuritis

›Bedside POCUS applicable

›B-scan orbital ultrasound

›Optic neuritis sign — 30-degree test

›Fluid in optic nerve sheath on B-scan

›Limited specificity — supporting test only

›Role limitations

›Cannot replace MRI for nerve enhancement or brain lesion assessment

›Operator-dependent

›Useful as adjunct in resource-limited or urgent bedside setting

Additional special tests

›Visual evoked potentials (VEPs)

›P100 latency prolongation

›Supports optic nerve demyelination

›Useful for confirming subclinical ON

›Does not differentiate subtypes acutely

›Amplitude reduction

›Correlates with axonal loss severity

›Persistent amplitude reduction indicates structural damage

›Optical coherence tomography (OCT)

›Peripapillary retinal nerve fiber layer (pRNFL) thickness

›May be normal or swollen acutely

›Chronic thinning indicates permanent axonal loss

›Useful for monitoring and prognostication

›Macular ganglion cell layer

›Sensitive marker of retinal ganglion cell loss

›Correlates with long-term visual function

07Disposition/dispo41

Admission indications

›Inpatient admission criteria

›Severe bilateral vision loss or NLP vision

›NMOSD pattern requiring IV steroids and urgent PLEX planning

›Cannot manage safely as outpatient

›Concurrent myelitis or acute neurologic deficit

›Brainstem involvement

›Acute spinal cord syndrome

›Area postrema syndrome

›Intractable nausea and vomiting preventing oral medications

›IV rehydration and antiemetics required

›Inability to tolerate oral medications

›Severe nausea or dysphagia

›IV steroid infusion mandated

Outpatient infusion or observation

›Infusion center approach for typical ON

›Mild to moderate typical unilateral ON

›Preserved functional vision

›Able to attend daily infusion over 3 days

›IV methylprednisolone 1 g/day x 3 days as outpatient infusion

›Followed by oral prednisone taper if needed

›Blood glucose and blood pressure monitoring

›Patient reliability and transport confirmed

›Return precautions provided

›Ophthalmology and neurology follow-up arranged

Discharge criteria and follow-up

›Criteria for discharge

›Unilateral typical ON with preserved functional vision

08Treatment/t83

Acute corticosteroid therapy

›High-dose corticosteroids — first-line acute treatment

›IV methylprednisolone

›1 g IV daily for 3 days

›Hastens visual recovery — does not improve final visual outcome in typical ON

›Class I evidence (ONTT, NEJM 1992)

›High-dose oral prednisone — bioequivalent alternative

›1,250 mg/day orally for 3 days

›Shown equivalent to IV in RCT (Morrow et al, JAMA Neurology 2018)

›May use when IV access unavailable or infusion center not accessible

›Optional oral taper after pulse

›Prednisone 1 mg/kg/day for 11 days

›Followed by 3-day taper

›Reduces rebound inflammation in some protocols

›Steroid cautions

›Low-dose oral prednisone alone — contraindicated as sole therapy

›1 mg/kg/day without pulse increases recurrence risk (ONTT)

›Class I evidence against low-dose oral prednisone monotherapy

›Monitoring during steroid therapy

›Blood glucose — diabetic and non-diabetic patients

›Blood pressure

›Psychiatric side effects — insomnia, mood changes

›Gastrointestinal protection — proton pump inhibitor PRN

Steroid-refractory treatment

›Plasma exchange (PLEX)

›Indication

›Steroid-refractory vision loss — especially NMOSD

›Severe vision loss with inadequate response to IV methylprednisolone

›Timing

›Early initiation (within 48 hours of steroid failure) improves outcomes

›Typically 5–7 exchanges over 10–14 days

›Mechanism

›Removes pathogenic antibodies including AQP4-IgG and MOG-IgG

›Reduces complement activation in NMOSD

›IVIG — alternative when PLEX unavailable

›2 g/kg IV divided over 2–5 days

›Less evidence than PLEX for acute severe ON

›Considered for MOGAD relapse and PLEX-ineligible patients

›Infusion rate titration to prevent reactions

Atypical ON — extended steroid protocol

›NMOSD and MOGAD acute regimen

›IV methylprednisolone 1 g/day for 3–5 days

›Longer course than typical ON

›Followed by prolonged oral prednisone taper over 4–6 months

›Rationale

›Rapid steroid taper risks rebound or early relapse

›MOGAD particularly prone to steroid-dependent course

›Close outpatient monitoring required

Long-term disease-modifying therapy

›MS — disease-modifying therapy (DMT) initiation

›Indication

›One or more white matter lesions on brain MRI at time of ON

›High risk for future relapse and MS diagnosis

›Early high-efficacy DMT preferred

›Natalizumab, ocrelizumab, alemtuzumab, cladribine

›Shared decision-making with neurology

›Caution

›MS therapies including interferon-beta and natalizumab can worsen NMOSD

›Subtype differentiation is critical before initiating any DMT

›NMOSD — maintenance immunosuppression

›FDA-approved biologics

›Eculizumab (complement C5 inhibitor)

›Satralizumab (IL-6 receptor antagonist)

›Inebilizumab (anti-CD19 B-cell depleter)

›Conventional options when biologics unavailable

›Rituximab (off-label) — anti-CD20

›Azathioprine with or without low-dose prednisone

›Mycophenolate mofetil

›MOGAD — relapse prevention

›IVIG for relapse prevention

›2 g/kg IV every 4–8 weeks (individualized)

›Most evidence-supported option

›Prolonged oral prednisone taper for initial episode

›High risk of early relapse with rapid taper

›Maintenance low-dose steroids in some protocols

Supportive and symptomatic treatment

›Pain management

›Periocular pain with eye movement — usually self-limited

›NSAIDs — ibuprofen 400–600 mg PO every 6–8 hours PRN

›Acetaminophen 500–1,000 mg PO every 6 hours PRN

›Avoid opioids for routine periocular pain

›Self-resolving within 1–2 weeks in typical ON

›Uhthoff phenomenon counseling

›Avoid overheating — cool environment, avoiding hot baths or exercise in heat

›Benign and transient

›Does not indicate relapse

›Cooling vest or cold beverages during exercise

›Practical adaptation strategies

09Special Populations/sp58

Pregnancy

›Pregnancy considerations for optic neuritis

›Risk of relapse in MS and NMOSD around delivery and postpartum

›Relapse risk reduced during pregnancy

›Relapse risk increased in first 3–6 months postpartum

›Acute treatment in pregnancy

›IV methylprednisolone — acceptable for severe acute ON

›Short course preferred — minimize fetal exposure

›Oral steroid taper — risk-benefit with obstetrics

›Avoid during pregnancy

›Most MS DMTs — teratogenic (natalizumab, alemtuzumab, cladribine, fingolimod)

›IVIG — relatively safe for MOGAD relapse prevention if needed

›NMOSD in pregnancy

›High-risk group — eculizumab safety data limited

›Rituximab — used in some cases with multidisciplinary decision

›Urgent neurology and maternal-fetal medicine comanagement

›Imaging

›MRI brain and orbits without gadolinium preferred

›Gadolinium — avoid in first trimester; limited use thereafter if critical

›No ionizing radiation required for optic nerve imaging

Geriatric

›Older adult considerations

›Atypical presentation common

›Painless or minimal pain — lower threshold for ischemic workup

›GCA must be excluded in all patients above 50 with acute vision loss

›Ischemic optic neuropathy versus ON

›NAION — more common than ON in patients above 50

›Altitudinal visual field defect, disc edema with splinter hemorrhages

10Background/b65

Epidemiology

›Frequency and demographics

›Annual incidence

›Approximately 6.4 per 100,000 in the United States

›Most common cause of subacute optic neuropathy in young adults

›Age distribution

›Peak incidence age 20–45 years

›Mean age approximately 32 years in ONTT

›Sex distribution

›Female to male ratio 2–3 to 1 for MS-associated ON

›Female to male ratio 9 to 1 for NMOSD

›Association with demyelinating disease

›Frequently initial presenting event of MS

›50% of MS patients experience ON at some point

›Cumulative 15-year MS risk after first ON episode is 50% overall

Pathophysiology

›Mechanisms of optic nerve injury

›Inflammatory demyelination

›T-cell mediated inflammation targeting myelin in MS-associated ON

›AQP4-IgG mediated astrocyte destruction in NMOSD

›MOG-IgG mediated myelin disruption in MOGAD

›Conduction slowing

›Demyelination causes slowed and unreliable electrical conduction

›Explains VEP latency prolongation

›Temperature sensitivity explains Uhthoff phenomenon

›Axonal injury

›Inflammation mediates axonal loss in addition to demyelination

›Axonal loss irreversible — determines final visual outcome

11Patient Discharge Instructions/pdi43

copy discharge instructions

›Optic neuritis home care

›Steroid medication — take exactly as prescribed

›Do not stop or taper early without physician guidance

›Take with food to reduce stomach upset

›Blood sugar monitoring

›Steroids can temporarily raise blood sugar

›Check glucose daily if diabetic

›Sleep and activity

›Rest your eyes when fatigued

›Avoid driving if vision significantly reduced

›Heat and exercise

›Avoid hot baths, saunas, or strenuous exercise in heat

›Vision may temporarily worsen with heat (Uhthoff phenomenon) — this is normal and not a relapse

›Warning signs — return to ER immediately

›Vision becomes worse in either eye

›New vision loss in the other eye

›Vision loss not improving or worsening after 2 weeks

›New neurologic symptoms

›Numbness or tingling in arms, legs, or face

›Weakness in arms or legs

›Difficulty walking or balance problems

›Bladder or bowel control loss

›Intractable nausea or vomiting

›Unable to keep fluids or medications down

›Severe or worsening eye pain

›Pain not improving with anti-inflammatories

›New severe headache

12References/r33

Guidelines and key sources

›Landmark trials

›Optic Neuritis Treatment Trial (ONTT)

›Beck RW et al. NEJM 1992 — randomized controlled trial corticosteroids in acute ON

›Established IV methylprednisolone as standard acute treatment

›15-year follow-up data — MS risk stratification by MRI lesion burden

›Morrow SA et al. JAMA Neurology 2018

›RCT demonstrating high-dose oral prednisone bioequivalent to IV methylprednisolone

›Supports oral route as acceptable alternative for typical ON

›Society guidelines and criteria

›McDonald Criteria 2017 revision

›Dissemination in space and time criteria for MS diagnosis

›MRI lesion location criteria

›ACR Appropriateness Criteria — Vision Loss (2025)

›MRI orbits with and without contrast — usually appropriate for suspected optic nerve pathology

›Expert Panel on Neurological Imaging, Friedman ER et al.

›ACR Appropriateness Criteria — Demyelinating Diseases (2026)

›Expert Panel on Neurologic Imaging, Kalnins A et al.

›Key review articles

›Toosy AT, Mason DF, Miller DH. Optic Neuritis. Lancet Neurology 2014

›Comprehensive pathophysiology and clinical review

›Bennett JL, Costello F, Chen JJ et al. Optic Neuritis and Autoimmune Optic Neuropathies. Lancet Neurology 2023

›Advances in diagnosis and treatment including MOGAD

›Kraker JA, Chen JJ. An Update on Optic Neuritis. Journal of Neurology 2023

›Alchaki AR. Neurologic Clinics 2026 — acute and maintenance management including MS, NMOSD, MOGAD

›Bergeron E, Bouffard MA. Evidence-Based Management of Optic Neuritis. Curr Opin Ophthalmol 2024

›Wingerchuk DM, Lucchinetti CF. NMOSD. NEJM 2022

›Fraser JA, Son M, Vinokurtseva A. Sudden Vision Loss. American Family Physician 2025

Learn More: Optic Neuritis→

Comprehensive Clinical Review

Structured, evidence-informed, long-form analysis for deeper understanding.

Evidence & Review

Reviewed by SymptomDx Medical Team · Last reviewed August 18, 2026

SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.